-- In July 2008, HGS initiated dosing in the safety lead-in to a randomized Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in patients with advanced hepatocellular cancer (HCC), which accounts for 80- 90% of all liver cancers. The Company presented preclinical data that support the HCC study at the 2008 American Association for Cancer Research annual meeting in April.
In May 2008, HGS initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced solid tumors. Results of the study will also help identify the recommended dose for Phase 2 trials.
In April 2008, HGS reacquired rights to its TRAIL receptor antibodies HGS- ETR1 and HGS-ETR2 (lexatumumab) from GSK.
Darapladib: Phase 3 Plans Announced by GSK
In April 2008, GSK announced that it intends to advance darapladib to Phase 3 clinical trials as a potential treatment for atherosclerosis. Darapladib, a small-molecule inhibitor of Lp-PLA2, was discovered by GSK based on HGS technology. HGS will receive a 10% royalty on worldwide sales of darapladib if it is commercialized, and also has a 20% co-promotion option in North America and Europe.
HGS management will hold a conference call to discuss this announcement
today at 5 PM Eastern Time. Investors may listen to the call by dialing
888-686-9685 or 913-312-0412, passcode 4551709, five to 10 minutes before
the start of the call. A replay of the conference call will be available
within a few hours after the call ends. Investors may listen to the replay
by dialing 888-203-1112 or 719-457-0820, confirmation code 4551709. Today's
conference call also will be webcast and can be accessed at http://www.hgsi.com.
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved